Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Metastatic non-small cell lung cancer is often treated with a combination of chemotherapy and immunotherapy. In patients over the age of 70, some are already in poor health and frail, requiring assistance with daily activities, for example. Older and/or frail individuals often do not tolerate standard-dose chemotherapy well, and their risk of side effects is higher than that of younger patients. For this reason, the SAKK 18/24 study is investigating how effective and safe chemotherapy is in patients over 70 years of age when the chemotherapy drugs are administered at lower doses than usual. T

Trial Details

NCT ID

NCT07020065

Phase

PHASE2

Sponsor

Swiss Cancer Institute

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Cemiplimab
Carboplatin
Pemetrexed & Gemcitabine
Paclitaxel

Locations (sample)

Fribourg, Villars-sur-Glâne, Switzerland|46.80237,7.15128
Aarau, Switzerland|47.39254,8.04422
Baden, Switzerland|47.47333,8.30592
Basel, Switzerland|47.55839,7.57327
Bern, Switzerland|46.94809,7.44744

Key Eligibility Criteria

Informed Consent as documented by signature
Histologically or cytologically confirmed NSCLC. Mixed histology with small-cell component is not allowed.
Metastatic or advanced or recurrent NSCLC without a curative-intent treatment option (surgery or chemo-radiotherapy).
PD-L1 \<50% by local testing (SP 142 excluded)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →